Market

Gland Pharma's Visakhapatnam Special Economic Zone Sterile Oncology Facility recently achieved a No Action Indicated status following a USFDA inspection with zero Form 483 observations. This significant regulatory outcome underscores the firm’s commitment to maintaining the highest quality

The high cost of managing PRRS outbreaks in Mexico has become a primary threat to the business survival of multi-generational family farming operations. Across the North American continent, the swine industry has reached a pivotal moment in its struggle against Porcine Reproductive and Respiratory

The U.S. Food and Drug Administration has historically maintained a tight grip on international regulatory priorities to prevent them from drifting away from its own preferences. This level of control is necessary because the global medical device industry currently operates within a fragmented

Historical failures in the vitiligo pipeline, such as the cancellation of the AC##4 trial in 2016, highlight the difficulty of establishing a global site network. The recent publication of the Viti-Up Phase 3 clinical trial results in The Lancet marks a transformative moment for dermatologic

For the 15,000 Americans living with Duchenne muscular dystrophy, the three-month regulatory delay represents a critical window where irreversible physical decline remains a constant threat. This extension, moving the target decision date from August to November 22, 2026, occurred after the Food

This digital initiative addresses long-standing inefficiencies by providing a public mechanism to verify the legal status of medical devices sold throughout the country. For many years, the Mexican medical device market struggled with a lack of transparency, where paper-based records led to